Changes in protein serum levels during stem cell transplantation

Elisabetta Metafuni, Sabrina Giammarco, Daniela Giovanna De Ritis, Monica Rossi, Francesco Corrente, Nicola Piccirillo, Andrea Paolo Bacigalupo, Simona Sica, Patrizia Chiusolo

Research output: Contribution to journalArticle

1 Citation (Scopus)


Background: GvHD is one of the major complication after stem cell transplantation affecting transplant-related mortality. Throughout the last years, many serum proteins were been proposed as possible biomarkers for GvHD. Aims: We studied the trend of five of the most studied serum proteins to evaluate whether a correlation exists between proteins concentration and post-HSCT outcomes. Materials and methods: We measured serum concentration of REG3α, ST2, B-cell activating factor (BAFF), CXCL9 and elafin in a cohort of 77 patients submitted to Hematopoietic allogeneic stem cell transplantation (HSCT) in our department. Blood samples were been collected at baseline, day +30, GvHD onset and GvHD resolution. Results: REG3α levels showed an association only with acute GvHD. Elafin and ST2 levels varied according to both acute and chronic GvHD occurrence. BAFF concentration showed an inverse association with acute GvHD development. Interestingly, baseline BAFF and ST2 levels predicted post-HSCT survival. No associations were found for CXCL9. Conclusions: Except for CXCL9, the protein levels seem to change according to GvHD development, independently from organ involvement and grading. Pretransplant ST2 and BAFF appeared to be predictors for survival after HSCT.
Original languageEnglish
Pages (from-to)711-718
Number of pages8
JournalEuropean Journal of Clinical Investigation
Publication statusPublished - 2017


  • Biochemistry
  • Biomarkers
  • Clinical Biochemistry
  • GVHD
  • HSCT
  • TRM
  • serum protein


Dive into the research topics of 'Changes in protein serum levels during stem cell transplantation'. Together they form a unique fingerprint.

Cite this